TransEnterix, Inc. announced the Company received FDA 510(k) clearance for its Senhance Ultrasonic System. Advanced energy devices are used within...
The use of PCC for reversing coagulopathy in multiply injured patients with pelvic and/or lower extremity fractures remains unclear. This study assesses the efficacy of PCC for reversing coagulopathy in this group of patients.
This retrospective study used propensity matching to compare 81 trauma patients with high energy lower limb and pelvic fractures who had received either prothrombin complex concentrate or fresh frozen plasma for coagulopathy of trauma.
The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.
Biotronik announced it has received FDA approval for its Pro-Kinetic Energy cobalt chromium (CoCr) coronary stent system. The company gained...
Herein, we provide an evidence-based rationale for the use of low-energy SLT repeated annually as primary therapy for mild to moderate primary open-angle glaucoma or high-risk ocular hypertension.
The effects of empagliflozin treatment on hepatocellular lipid content, liver energy metabolism and body composition will be investigated in a...
The proposed multicenter study will test the effect of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (ExQW, Bydureon®) on...
The FDA has approved the Itrevia DX implantable cardioverter defibrillator (ICD), from Biotronik, for patients with complex heart rhythm conditions....
St. Jude Medical, Inc. has announced U.S. approval of BurstDR stimulation, a physician-designed form of spinal cord stimulation (SCS) clinically...